Rationale for off-label treatments use in primary progressive multiple sclerosis: A review of the literature
CONCLUSION: The literature lacks dedicated studies to support the off-label use of these disease-modifying therapies in PPMS. However, some limited data are available in the literature suggesting that the use of rituximab and cyclophosphamide could potentially be of some interest in specific subpopulations.PMID:35851485 | DOI:10.1016/j.neurol.2022.02.461 (Source: Revue Neurologique)
Source: Revue Neurologique - July 19, 2022 Category: Neurology Authors: T Chedid X Moisset P Clavelou Source Type: research

Successful Elimination of SARS-CoV-2 Following Vaccination with BNT162b2 after Prolonged Viral Infection in an Immunocompromised Lymphoma Patient
Intern Med. 2022;61(14):2215-2219. doi: 10.2169/internalmedicine.9513-22. Epub 2022 Jul 15.ABSTRACTA 52-year-old man with mantle cell lymphoma treated with bendamustine and rituximab developed prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Despite elevated titers of anti-spike IgG antibody, protracted pancytopenia persisted for more than six months. Finally, the anti-SARS CoV-2 vaccine, BNT162b2, was administered, which improved his blood cell count and eliminated the virus. The increased anti-spike IgG titer and lymphocyte count after vaccination suggested that both humoral and cellular ...
Source: Internal Medicine - July 19, 2022 Category: Internal Medicine Authors: Masao Hagihara Yui Imai Tomoyuki Uchida Shin Ohara Morihiro Inoue Tomiyuki Sugi Keiko Mitamura Source Type: research

Rationale for off-label treatments use in primary progressive multiple sclerosis: A review of the literature
CONCLUSION: The literature lacks dedicated studies to support the off-label use of these disease-modifying therapies in PPMS. However, some limited data are available in the literature suggesting that the use of rituximab and cyclophosphamide could potentially be of some interest in specific subpopulations.PMID:35851485 | DOI:10.1016/j.neurol.2022.02.461 (Source: Revue Neurologique)
Source: Revue Neurologique - July 19, 2022 Category: Neurology Authors: T Chedid X Moisset P Clavelou Source Type: research

Rituximab-Induced Hypogammaglobulinemia and Risk of Infection in Neuromyelitis Optica Spectrum Disorders: A 14-Year Real-Life Experience
Discussion Over 14 years of long-term RTX treatment, IgG levels gradually decreased, and the frequency of hypo-IgG increased to 41% of the patients. Patients with prolonged memory B-cell depletion after RTX, previous mitoxantrone history, hypo-IgG at baseline, or obesity were at risk of developing RTX-induced hypogammaglobulinemia. Nevertheless, infection rates remained low during treatment, and reduced immunoglobulin levels were not associated with an increased incidence of infections. (Source: Neurology Neuroimmunology and Neuroinflammation)
Source: Neurology Neuroimmunology and Neuroinflammation - July 19, 2022 Category: Neurology Authors: Kim, S.-H., Park, N. Y., Kim, K. H., Hyun, J.-W., Kim, H. J. Tags: All Demyelinating disease (CNS), Devic's syndrome Research Article Source Type: research

Secondary Immune Deficiency and Primary Immune Deficiency Crossovers: Hematological Malignancies and Autoimmune Diseases
Primary immunodeficiencies (PIDs), a heterogenous group of inborn errors of immunity, are predetermined at birth but may evolve with age, leading to a variable clinical and laboratory presentation. In contrast, secondary immunodeficiencies (SIDs) are acquired declines of immune cell counts and or/function. The most common type of SID is a decreased antibody level occurring as a consequence of extrinsic influences, such as an underlying condition or a side effect of some medications used to treat hematological malignancies and autoimmune disorders. Paradoxically, immune deficiencies initially attributed to secondary causes ...
Source: Frontiers in Immunology - July 18, 2022 Category: Allergy & Immunology Source Type: research

A Multicenter Study of 239 Patients Aged Over 70  Years With Diffuse Large B-Cell Lymphoma in China
Conclusion: Our study presents the clinical profiles and survival outcomes of elderly patients with DLBCL in China. Treatment of these patients requires careful evaluation of toxicities and benefits. To this end, a prognosis model, such as comprehensive geriatric assessment, is required in clinical practice to optimally manage elderly patients with DLBCL. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - July 18, 2022 Category: Drugs & Pharmacology Source Type: research

Successful Rituximab Therapy for Pediatric Antiphospholipid-Related Chorea: A Case Report and Review of the Literature
We present a case of a therapy-resistant chorea, successfully treated with rituximab. Furthermore, we give an overview of the existing literature concerning rituximab for the treatment of chorea in children. Our findings indicate that rituximab can be considered a safe option to treat antiphospholipid syndrome-related chorea in children. [...] Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, GermanyArticle in Thieme eJournals: Table of contents  |  Abstract  |  Full text (Source: Neuropediatrics)
Source: Neuropediatrics - July 17, 2022 Category: Neurology Authors: D'hont, Alexia De Wachter, Matthias Driesen, Yentl Sabato, Vito Joos, Rik Ceulemans, Berten Tags: Short Communication Source Type: research

Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-cell Lymphomas
Approximately 50-60% of patients with aggressive B-cell non-Hodgkin lymphomas (B-NHL) are cured with anthracycline- and rituximab-based induction.1-3 However, outcomes of patients with relapsed or refractory (R/R) B-NHL are poor, particularly in those unable to receive autologous hematopoietic cell transplantation (HCT) with overall survival of 4-6 months.4-6 Anti-CD19 chimeric antigen receptor (CAR) T cell therapy has shown significant promise for treatment of R/R B-NHL leading to the FDA approval of three products: axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel). (S...
Source: Biology of Blood and Marrow Transplantation - July 15, 2022 Category: Hematology Authors: Peter A. Riedell, Wei-Ting Hwang, Loretta J. Nastoupil, Martina Pennisi, Joseph P. McGuirk, Richard T. Maziarz, Veronika Bachanova, Olalekan O. Oluwole, Jamie Brower, Oscar A. Flores, Nausheen Ahmed, Levanto Schachter, Kharmen Bharucha, Bhagirathbhai R. D Source Type: research

Rituximab in juvenile myasthenia gravis-an international cohort study and literature review
Eur J Paediatr Neurol. 2022 Jun 25;40:5-10. doi: 10.1016/j.ejpn.2022.06.009. Online ahead of print.ABSTRACTJuvenile myasthenia gravis (JMG) is a rare, antibody-mediated disorder of the neuromuscular junction. Treatment strategies in JMG are largely informed by adult MG treatments as the pathophysiology is similar. Rituximab is increasingly considered as a treatment option in refractory JMG but has not yet been systematically investigated in this patient group We conducted a retrospective study from five international centres with expertise in paediatric myasthenia. 10 JMG patients treated with rituximab were identified. Fo...
Source: European Journal of Paediatric Neurology - July 14, 2022 Category: Neurology Authors: Sithara Ramdas Adela Della Marina Monique M Ryan Kenneth McWilliam Andrea Klein David Jacquier Setareh Alabaf Anne-Marie Childs Deepak Parasuraman David Beeson Jacqueline Palace Heinz Jungbluth Source Type: research

Rituximab in juvenile myasthenia gravis-an international cohort study and literature review
Eur J Paediatr Neurol. 2022 Jun 25;40:5-10. doi: 10.1016/j.ejpn.2022.06.009. Online ahead of print.ABSTRACTJuvenile myasthenia gravis (JMG) is a rare, antibody-mediated disorder of the neuromuscular junction. Treatment strategies in JMG are largely informed by adult MG treatments as the pathophysiology is similar. Rituximab is increasingly considered as a treatment option in refractory JMG but has not yet been systematically investigated in this patient group We conducted a retrospective study from five international centres with expertise in paediatric myasthenia. 10 JMG patients treated with rituximab were identified. Fo...
Source: European Journal of Paediatric Neurology - July 14, 2022 Category: Neurology Authors: Sithara Ramdas Adela Della Marina Monique M Ryan Kenneth McWilliam Andrea Klein David Jacquier Setareh Alabaf Anne-Marie Childs Deepak Parasuraman David Beeson Jacqueline Palace Heinz Jungbluth Source Type: research

Rituximab in juvenile myasthenia gravis-an international cohort study and literature review
Eur J Paediatr Neurol. 2022 Jun 25;40:5-10. doi: 10.1016/j.ejpn.2022.06.009. Online ahead of print.ABSTRACTJuvenile myasthenia gravis (JMG) is a rare, antibody-mediated disorder of the neuromuscular junction. Treatment strategies in JMG are largely informed by adult MG treatments as the pathophysiology is similar. Rituximab is increasingly considered as a treatment option in refractory JMG but has not yet been systematically investigated in this patient group We conducted a retrospective study from five international centres with expertise in paediatric myasthenia. 10 JMG patients treated with rituximab were identified. Fo...
Source: European Journal of Paediatric Neurology - July 14, 2022 Category: Neurology Authors: Sithara Ramdas Adela Della Marina Monique M Ryan Kenneth McWilliam Andrea Klein David Jacquier Setareh Alabaf Anne-Marie Childs Deepak Parasuraman David Beeson Jacqueline Palace Heinz Jungbluth Source Type: research

Rituximab in juvenile myasthenia gravis-an international cohort study and literature review
Eur J Paediatr Neurol. 2022 Jun 25;40:5-10. doi: 10.1016/j.ejpn.2022.06.009. Online ahead of print.ABSTRACTJuvenile myasthenia gravis (JMG) is a rare, antibody-mediated disorder of the neuromuscular junction. Treatment strategies in JMG are largely informed by adult MG treatments as the pathophysiology is similar. Rituximab is increasingly considered as a treatment option in refractory JMG but has not yet been systematically investigated in this patient group We conducted a retrospective study from five international centres with expertise in paediatric myasthenia. 10 JMG patients treated with rituximab were identified. Fo...
Source: European Journal of Paediatric Neurology - July 14, 2022 Category: Neurology Authors: Sithara Ramdas Adela Della Marina Monique M Ryan Kenneth McWilliam Andrea Klein David Jacquier Setareh Alabaf Anne-Marie Childs Deepak Parasuraman David Beeson Jacqueline Palace Heinz Jungbluth Source Type: research

Rituximab in juvenile myasthenia gravis-an international cohort study and literature review
Eur J Paediatr Neurol. 2022 Jun 25;40:5-10. doi: 10.1016/j.ejpn.2022.06.009. Online ahead of print.ABSTRACTJuvenile myasthenia gravis (JMG) is a rare, antibody-mediated disorder of the neuromuscular junction. Treatment strategies in JMG are largely informed by adult MG treatments as the pathophysiology is similar. Rituximab is increasingly considered as a treatment option in refractory JMG but has not yet been systematically investigated in this patient group We conducted a retrospective study from five international centres with expertise in paediatric myasthenia. 10 JMG patients treated with rituximab were identified. Fo...
Source: European Journal of Paediatric Neurology - July 14, 2022 Category: Neurology Authors: Sithara Ramdas Adela Della Marina Monique M Ryan Kenneth McWilliam Andrea Klein David Jacquier Setareh Alabaf Anne-Marie Childs Deepak Parasuraman David Beeson Jacqueline Palace Heinz Jungbluth Source Type: research

Rituximab in juvenile myasthenia gravis-an international cohort study and literature review
Eur J Paediatr Neurol. 2022 Jun 25;40:5-10. doi: 10.1016/j.ejpn.2022.06.009. Online ahead of print.ABSTRACTJuvenile myasthenia gravis (JMG) is a rare, antibody-mediated disorder of the neuromuscular junction. Treatment strategies in JMG are largely informed by adult MG treatments as the pathophysiology is similar. Rituximab is increasingly considered as a treatment option in refractory JMG but has not yet been systematically investigated in this patient group We conducted a retrospective study from five international centres with expertise in paediatric myasthenia. 10 JMG patients treated with rituximab were identified. Fo...
Source: European Journal of Paediatric Neurology - July 14, 2022 Category: Neurology Authors: Sithara Ramdas Adela Della Marina Monique M Ryan Kenneth McWilliam Andrea Klein David Jacquier Setareh Alabaf Anne-Marie Childs Deepak Parasuraman David Beeson Jacqueline Palace Heinz Jungbluth Source Type: research

Rituximab in juvenile myasthenia gravis-an international cohort study and literature review
Eur J Paediatr Neurol. 2022 Jun 25;40:5-10. doi: 10.1016/j.ejpn.2022.06.009. Online ahead of print.ABSTRACTJuvenile myasthenia gravis (JMG) is a rare, antibody-mediated disorder of the neuromuscular junction. Treatment strategies in JMG are largely informed by adult MG treatments as the pathophysiology is similar. Rituximab is increasingly considered as a treatment option in refractory JMG but has not yet been systematically investigated in this patient group We conducted a retrospective study from five international centres with expertise in paediatric myasthenia. 10 JMG patients treated with rituximab were identified. Fo...
Source: European Journal of Paediatric Neurology - July 14, 2022 Category: Neurology Authors: Sithara Ramdas Adela Della Marina Monique M Ryan Kenneth McWilliam Andrea Klein David Jacquier Setareh Alabaf Anne-Marie Childs Deepak Parasuraman David Beeson Jacqueline Palace Heinz Jungbluth Source Type: research